ORIGINAL ARTICLE

Potential Immunological Advantage of Intravenous Mycophenolate Mofetil with Tacrolimus and Steroids in Primary Deceased Donor Liver Transplantation and Live Donor Liver Transplantation Without Antibody Induction

Ashokkumar Jain,¹ Rajeev Sharma,¹ Charlotte Ryan,² Georgious Tsoulfas,¹ Mark Orloff,¹ Peter Abt,¹ Randeep Kashyap,¹ Pam Batzold,¹ Lisa Sauberman,³ Saman Safadjou,¹ Maureen Graham,¹ and Adel Bozorgzadeh¹

¹Department of Surgery, Division of Solid Organ Transplantation, ²Department of Pathology, and ³Department of Pharmacy, University of Rochester Medical Center, Rochester, NY

With the current immunosuppressive regimens, graft loss secondary to immunological reasons after successful liver transplantation is a rarity; acute rejections, however, do occur, with the majority of them being steroid-responsive. The aim of the present study is to examine the rate of acute rejection with tacrolimus, intravenous (IV) mycophenolate mofetil (MMF), and steroids in primary deceased donor liver transplant (DDLT) and live donor liver transplant (LDLT) recipients. During the year 2005, 130 patients (mean age: 54.9 ± 10.8 , males: 84, females: 46, 112 DDLT and 18 LDLT) received primary liver transplantation. They were followed up for the incidence of acute rejection in the first 12 months. Liver biopsies were performed as clinically indicated; protocol liver biopsies were never performed. A total of 127 liver biopsies were performed. Thirty-two had a rejection activity index (RAI) score of \geq 3, of which 24 biopsies in 20 patients were not treated with a steroid bolus. Eight (6.1%) patients (mean RAI score: 5.1 ± 1.4) received 750 to 1500 mg of methylprednisolone over 3 days. Out of these, 2 were noncompliant, 4 were off MMF, and 1 was on cyclosporine. All patients responded to steroid therapy. None of the patients required any antibody preparation. In conclusion, IV MMF with tacrolimus and steroids is useful and required antirejection therapy in 6.1% of liver transplant recipients. *Liver Transpl* 14:202–209, 2008. \otimes 2008 AASLD.

Received July 2, 2007; accepted August 28, 2007.

The introduction of cyclosporine in the early 1980s almost doubled patient and graft survival after liver transplantation.¹⁻³ Steroid-resistant acute cellular rejection could be reversed with the use of monoclonal murine anti-CD3 (OKT3) preparation.⁴ With the introduction of tacrolimus in the early 1990s, the hepatic graft loss from acute or chronic rejection became a rarity.^{5,6} However, acute rejections after primary liver transplantation do occur, although with reduced incidence and severity.⁷⁻¹⁰ Most of the acute rejections can be easily reversed with the use of steroids and/or conversion to tacrolimus from cyclosporine A.¹¹⁻¹⁴ Newer

Abbreviations: Alk PO4, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CsA, cyclosporine A; DDLT, deceased donor liver transplant; ETOH, alcohol-induced cirrhosis; GGTP, gamma glutamyl transpeptidase; HAI, hepatitis activity index; HBV, hepatitis B viral infection–related cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus, hepatitis C viral infection–related cirrhosis; IV, intravenous; LDLT, live donor liver transplant; LTX, liver transplant; MELD, Model for End-Stage Liver Disease; MMF, mycophenolate mofetil; MPA, mycophenolic acid; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; Pred, prednisolone; PSC, primary sclerosing cholangitis; RAI, rejection activity index; Tacro, tacrolimus; SD, standard deviation; TTP, thrombotic thrombocytopenic purpura. Address reprint requests to Ashokkumar Jain, M.D., Department of Surgery, Division of Transplantation, University of Rochester Medical Center, Box SURG, 601 Elmwood Avenue, Rochester, NY 14642. Telephone: 585-275-2924; FAX: 585-506-0054; E-mail: ashok_jain@urmc.rochester.edu

DOI 10.1002/lt.21348 Published online in Wiley InterScience (www.interscience.wiley.com). immunosuppressive medications, mycophenolate mofetil (MMF) and chimeric and humanized antibody against interleukin 2 receptor, have been successfully used with calcineurin inhibitor and steroids to reduce the rate of acute rejection even further.¹⁵⁻¹⁷ Rapamune, a target of rapamycin inhibitor,¹⁸ had also been used with tacrolimus, and the initial results were very promising.¹⁹ Unfortunately, because of the increased rate of hepatic artery thrombosis²⁰ in primary liver transplantation, the Food and Drug Administration has prohibited its use for the first 30 days after liver transplantation.

MMF is an inosine monophosphate dehydrogenase inhibitor that prevents the de novo synthesis of purine in lymphocytes.^{21,22} The drug was initially used with cyclosporine in kidney transplantation with significant reduction in the rate of acute rejection. Subsequently, the drug was used in liver transplantation.²³ It showed a further reduction in acute rejection with better preservation of the renal function. However, in more than 50% of the patients, the drug was discontinued for gastrointestinal, bone marrow suppression, and other reasons.^{15,24} All the trials in kidney and liver transplantation were performed with an oral formulation of MMF. There are several reports to suggest a reduced rate of acute cellular rejection after primary liver transplantation with the use of oral MMF, tacrolimus, and steroids,^{16,24,25} but the fact remains that rejection does occur.

Bioavailability of oral MMF in liver transplant (LTx) recipients is different compared to that in healthy volunteers and kidney transplant, heart transplant, and lung transplant recipients, for whom the absorption is more than 90%. In LTx patients, it was found that the trough concentration of mycophenolic acid (MPA; active metabolite of MMF) improved during the first 30 days post transplantation,²⁶ and bioavailability was almost double 4 weeks post LTx compared to 1 week post LTx.²⁷ At our institution, we have been using intravenous (IV) MMF in immediate post-LTx patients until the patients can take oral MMF. We initially reported a retrospective analysis of 28 live donor liver transplants (LDLTs) using IV MMF with a 10.5% rate of late acute rejections; in the majority of those patients, compliance was in question.²⁸ We subsequently performed a pharmacokinetic study in LTx recipients and found that the bioavailability of oral MMF and peak concentration of MPA were less than 50% in comparison with IV MMF.²⁹

The aim of the present study is to examine the rate of acute rejection, severity of rejection, and response to antirejection therapy in primary deceased donor liver transplant (DDLT) and LDLT recipients.

PATIENTS AND METHODS

Between January 2005 and December 2005, 130 consecutive, nonrandomized patients with primary liver transplantation (112 DDLT and 18 LDLT) were examined according to an institute review board–approved protocol. There were 84 male and 46 female patients. The mean age of the recipients was 54.9 ± 10.8 years (DDLT, 55.3 ± 11.4 ; LDLT, 52.1 ± 5.9), and the mean donor age was 49.3 \pm 16.2 years (DDLT, 51.2 \pm 16.2; LDLT, 37.7 \pm 10.5). The overall mean Model for End-Stage Liver Disease score at the time of LTx was 20.4 \pm 9.6 (DDLT, 21.6 \pm 9.8; LDLT, 13.5 \pm 4.6). The primary diagnosis of the patients is shown in Table 1. Post transplantation, the incidence and severity of rejection, treatment and response of rejection, and liver function for the first 12 months were examined. Biopsies were performed as clinically indicated. Protocol biopsies were never performed. All biopsies were reviewed by the same pathologist and scored for rejection activity index (RAI; per Banff's criteria³⁰), hepatitis activity index, fibrosis, cholestasis, steatohepatitis, and ischemic injury. Immunosuppression at various time intervals from LTx for DDLT and LDLT is given in Table 2.

Immunosuppression Protocol

All patients were initiated on IV MMF at a dose of 1 g twice daily (constant 2-hour infusion) and then converted to oral MMF at a dose of 1 g twice daily when they would tolerate oral intake. In addition, study patients received oral tacrolimus, starting at a dose of 0.05 mg/kg twice daily. The dose of tacrolimus was adjusted according to the clinical conditions, and the target trough levels were normally maintained around 8-10 ng/mL in the first month and then gradually reduced to 6 ng/mL by 12 months. The patients also received 500 mg of methylprednisolone prior to reperfusion of the liver. A total dose of 200 mg/day of methylprednisolone was given over 5 days with 20 mg of prednisolone thereafter as maintenance.

RESULTS

Every patient was followed up for a period of 12 months to evaluate the rate of rejection. A total of 127 liver biopsies were performed as clinically indicated. Sixtyseven patients had 1 liver biopsy, 31 had 2 liver biopsies, 15 had 3 liver biopsies, 8 had 4 liver biopsies, and 6 had 5 liver biopsies.

Out of these, 71 biopsies were performed for patients with hepatitis C virus (HCV) infection (1.6 biopsies per patient), and 56 were performed for non-HCV patients (0.6 biopsies per patient). The distribution of RAI is given in Table 3. Out of 127 biopsies, 95 biopsies (74.8%) had an RAI score of ≤ 2 (0: 15, 1: 39, 2: 41), and the remaining 32 (25.2%) had an RAI score of ≥ 3 . Out of 32 biopsies with an RAI score of ≥ 3 , 24 biopsies in 20 patients were not treated with steroid bolus because of associated HCV infection (n = 12 patients), bile duct stricture (n = 3 patients), and other associated conditions (n = 5 patients; Table 4).

The remaining 8 patients (DDLT: 7, LDLT: 1, mean RAI score: 5.1 ± 1.4) received 750 to 1500 mg of methylprednisolone over 3 days. Details of these patients are summarized in Table 5. One patient had moderate cholestasis (#71) and ischemic injury, and another (#109) had moderate central cholestasis and 30% steatosis; however they both responded to steroid bolus. Three patients had subtherapeutic tacrolimus trough concentrations (<5.0 ng/mL). One patient (#113) was on a

	DDLT	LDLT	Overall
Demographics			
Male	75	9	84
Female	37	9	46
Mean age recipients (years)	55.3 ± 11.4	52.1 ± 5.9	54.9 ± 10.8
Mean age donors (years)	51.2 ± 16.2	37.7 ± 10.5	49.3 ± 16.2
Mean MELD score	21.6 ± 9.8	13.5 ± 4.6	20.4 ± 9.6
Diagnosis			
HCV	37	8	45
ETOH	30	5	35
PBC	4	2	6
Autoimmune	6	0	6
PSC	3	0	3
NASH	3	0	3
Hemochromatosis	2	0	2
HBV	3	0	3
Sarcoidosis	2	0	2
Acute fulminant hepatic failure	1	0	1
Biliary atresia	1	0	1
Cryptogenic	19	3	22
HCC without cirrhosis	1	0	1

Abbreviations: DDLT, deceased donor liver transplant; ETOH, alcohol-induced cirrhosis; HBV, hepatitis B viral infection–related cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C viral infection–related cirrhosis; LDLT, live donor liver transplant; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.

*Twenty-three patients also had HCC.

microemulsion formulation of cyclosporine without MMF, and another 3 patients (#83, LDLT; #109 and #121, DDLT) were not on MMF at the time of rejection. The mean time to rejection was 74.0 ± 76.2 days post transplant. Two patients (#80 and #92) were noncompliant for taking immunosuppressive medication. Seven patients are currently alive with nearly normal liver function. All patients responded to steroid therapy. None of the patients received monoclonal antibodies for induction or as treatment for rejection.

DISCUSSION

Despite improvement in patient survival and graft survival with an extremely low rate of graft loss from acute or chronic rejection, acute rejection does occur with varying frequencies. The majority are steroid-responsive; steroid-resistant rejections, however, are also cited in up to 36% of cases (Table 6).

The rate of acute cellular rejection in the US multicenter trial³¹ was 58.55% in the tacrolimus group and 65.03% in the cyclosporine group. Corticosteroid-resistant rejection occurred under the tacrolimus group and cyclosporine group in 16.34% and 30.82% of patients, and refractory rejection occurred in 2.28% and 12.03% of patients, respectively. In the European multicenter trial,³² the rates of acute rejection were 40.5% for tacrolimus and 49.8% for cyclosporine. For refractory acute and chronic rejections, comparisons for tacrolimus versus cyclosporine were 0.8% versus 5.3% and 1.5% versus 5.3%, respectively. The highest rate of acute rejection of 83.2% was reported in the cyclosporine group in the Pittsburgh randomized trial.⁹ In several other studies, rates varying from 26% to 76% have been reported.^{7,8,16,33,34} The rate of acute rejection with tacrolimus and MMF in the Pittsburgh prospective randomized study²⁴ was 38.9% for triple versus 45.2% for double at 12 months. The lowest rate of acute rejection (10.7%) was reported for IV MMF with tacrolimus and steroids in LDLT with a mean follow-up of 17 months.²⁸

In the present study, the overall rate of acute rejection that required antirejection therapy in the first year post transplant was 6.1%. All patients were steroidresponsive. Out of the 8 patients who required steroid bolus, 2 patients were noncompliant for taking immunosuppressive agents, 3 patients had a subtherapeutic tacrolimus concentration, and 4 patients were not on MMF. Higher rates of rejection have been reported in patients who were not on MMF maintenance therapy.³⁵ The main difference in the present study is that we used the IV formulation of MMF, whereas in other studies oral MMF was used (Table 6).

Oral MMF is reported to have a bioavailability of >90% in healthy volunteers, kidney transplant recipients, and heart transplant recipients.^{28,36-38} In LTx patients, a progressive rise of the MPA trough concentration has been reported over the first month post transplant, which correlates with the rise in serum albumin.^{26,39} Also, an increase in the area under the curve after oral MMF at 2 weeks post LTx and after 4

Image: constraint of the							TABL	E 2. Im	munosi	uppress	TABLE 2. Immunosuppression (Mean Values)	an Value	SS)							
																			Pos	st LTx
MMFPredTacroMMFPredTacroMMFPredTacroTacroTacroTacroTacroMMFDoseDoseLevelDoseDoseDoseDoseDoseDoseDoseLevelDoseLevelDoseDoseLevelDoseDoseLevelDoseDoseLevelDose			1	Month			3]	Month			9	Month			6	Month			12 M	onths
$ \begin{array}{rcccccccccccccccccccccccccccccccccccc$	L	acro		Pred	Tacro	Tacro	MMF	Pred	Tacro	Tacro	MMF	Pred	Tacro	Tacro	MMF	Pred	Tacro	Tacro	MMF	Pred
	Dose	Level		Dose	Dose	Level	Dose	Dose	Dose	Level	Dose	Dose	Dose	Level	Dose	Dose	Dose	Level	Dose	Dose
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	(mg/	(ng/			(mg/			(mg/	(mg/	(ng/	(mg/	(mg/	(mg/	(ng/	(mg/	(mg/	(mg/		(mg/	(mg/
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	day)	mL)			day)			day)*	day)	mL)	day)*	day)*	day)	mL)	day)*	day)*	day)		day)*	day)*
$ \begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	6.0	10.2		18.8	5.2	8.0	2201	14.1	4.7	6.9	1245	10.0	5.0	8.3	1118	9.9	4.8	7.7	1023	9.5
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	6.0	10.3		18.7	5.3	8.0	2318	14.0	4.8	6.8	1216	10.0	4.8	8.2	1071	9.9	4.7	7.8	972	9.4
$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$		9.1	1929	19.4	4.9	8.2	1692	14.4	4.1	7.1	1333	10.3	5.9	8.9	1250	10.0	4.9	6.8	1200	10.0
114 0.4 0.2 0.1 332 0.2 0.4 0.1 61 0.2 0.6 0.4 92 0.1 0.1 0.5 119	~	9.9		19.0	5.1	8.1	2070	14.2	4.5	6.9	1264	10.1	5.2	8.5	1146	9.9	4.8	7.4	1065	9.6
	0.2	0.7	114	0.4	0.2	0.1	332	0.2	0.4	0.1	61	0.2	0.6	0.4	92	0.1	0.1	0.5	119	0.3

	TABL	E 3. Dis	stributio	on of RA	I	
	Biopsy	Biopsy	Biopsy	Biopsy	Biopsy	
	1	2	3	4	5	Total
RAI						
0	11	2	1	1	0	15
1	19	10	6	2	2	39
2	20	8	5	4	4	41
3	8	6	2	0	0	16
4	4	4	1	1	0	10
5	2	0	0	0	0	2
6	2	0	0	0	0	2
7	1	1	0	0	0	2
Total	67	31	15	8	6	127
HCV	34	20	10	4	3	71
Non-HCV	33	11	5	4	3	56
DDLT	56	27	15	8	6	112
LDLT	11	4	0	0	0	15
Abbreviation HCV, hepatransplant	atitis C	viral inf	ection;	LDLT; li		

weeks post LTx compared to the first week was also described.²⁷ However, a formal kinetic study in the immediate postoperative period in LTx recipients was never done. It was presumed that it would be the same as that of healthy volunteers and kidney transplant and heart transplant patients. Our previous study has shown that oral absorption of MMF in the second week is less than 50% and may be even less in the first week in LTx recipients. Also, the peak concentration of MPA with IV MMF was more than twice that of oral MMF.²⁹ A higher peak concentration and higher area under the curve of MPA with tacrolimus and steroids allow the hepatic allograft to survive without significant risk of acute rejection.

It is true that over a period of time clinicians have learnt not to treat borderline acute rejection (RAI < 3). Also, borderline acute rejection could be hard to distinguish from recurrent HCV. Indication of LTx with HCV infection has increased. Avoidance of steroid bolus in the presence of HCV recurrence with borderline rejection is currently practiced more frequently than in the past. In the present study, 20 patients (24 biopsies) had an RAI score of \geq 3 and were elected not to receive steroid bolus, whereas in some other studies, the same patients may have been treated. With 3 immunosuppressive agents as baseline maintenance, clinicians may feel more comfortable by adjusting the baseline maintenance doses of immunosuppressive agents rather than steroid bolus.

Despite this change in management of acute rejection, we feel that immediate postoperative administration of the IV formulation of MMF may have an advantage over oral MMF, for which bioavailability and peak concentration are less than 50% in LTx recipients.²⁹ Further immunological studies with qualitative differentiation of various lymphocytic populations using immunological markers and measurements of cytokine

	Mark by <b< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>TABLE</th><th>4.</th><th>sjecti</th><th>ion—N</th><th>Vo Tre</th><th>Rejection-No Treatment</th><th></th><th></th><th></th><th></th><th></th><th></th></b<>									TABLE	4.	sjecti	ion—N	Vo Tre	Rejection-No Treatment						
Marrier Thread Threa	The field The field <t< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th>Live</th><th>er Func</th><th>tion</th><th></th><th></th><th></th><th>Biop</th><th>sy Findi</th><th>ngs</th><th></th><th>Imm the</th><th>unosuppres Time of Rej</th><th>sion at ection</th><th></th></t<>							Live	er Func	tion				Biop	sy Findi	ngs		Imm the	unosuppres Time of Rej	sion at ection	
456 F Hapattisc 114 6.1 7.50 85.0 85.1 1134 3.0 1 None 3.3 0 0 1 Mapstisc 55.8 M Hapattisc 115 3.3 382.0 391.0 653.0 2861.0 4.0 6.0 2 None None 4.0 0 5 Hapattisc 54.3 M Hapattisc 146 19 107.0 174.0 159.0 450.1 10.0 140.0 10.0 140.0 10.0 140.0 10.0 140.0 10.0 140.0 10.0 140.0 10.0 10.0 10.0 10.0 140.0 10.0 <th>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</th> <th>Case No.</th> <th>Age (years)</th> <th></th> <th>Primary Diagnosis</th> <th></th> <th>Bilirubin (mg/dL)</th> <th>AST (u/L)</th> <th></th> <th>AIF</th> <th>GGTP (u/L)</th> <th>RAI</th> <th></th> <th>Fib- rosis</th> <th>Stea- tosis</th> <th>Chole- stasis</th> <th>Ischemic Injury</th> <th>Tacro Level (ng/mL)</th> <th>MMF (mg/day)</th> <th>Prednisone (mg/day)</th> <th>Reason for No Treatment</th>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Case No.	Age (years)		Primary Diagnosis		Bilirubin (mg/dL)	AST (u/L)		AIF	GGTP (u/L)	RAI		Fib- rosis	Stea- tosis	Chole- stasis	Ischemic Injury	Tacro Level (ng/mL)	MMF (mg/day)	Prednisone (mg/day)	Reason for No Treatment
558 M Hepatitis (115 33 382.0 391.0 655.0 2861.0 40 50 2 None None 40 0 5 Hepatitis (145 53 33.0 153.0 353.0 353.0 353.0 37		DDLT 2	45.6	ГL	Hepatitis C	114	6.1	75.0		851.0	1194.0	3.0		1	None	None	None	3.9	0	0	Hepatitis C vira infectior
31.2 M Hepatitis 146 59 94.0 128.0 153.4.0 37.0 12 1 Mine 10.7 0 10 <th< td=""><td>14 54.2 M Hipentifs 14 50.3 15.4 More More More More 10.7 0 10 Hermits 10 16 4.33 M Hipentifs 41 19 10.0 172.0 37.3 3 1 More Nore 11.6 2000 10 Hermits 10 Hermits 10 Hermits 10 10 Hermits 10 10 Hermits 10 10 10 Hermits 10</td><td>6</td><td>55.8</td><td>М</td><td>Hepatitis C</td><td></td><td>3.3</td><td>382.0</td><td>391.0</td><td>635.0</td><td>2861.0</td><td>4.0</td><td></td><td>2</td><td>None</td><td>None</td><td>None</td><td>4.0</td><td>0</td><td>Q</td><td>Hepatitis C vira infection</td></th<>	14 54.2 M Hipentifs 14 50.3 15.4 More More More More 10.7 0 10 Hermits 10 16 4.33 M Hipentifs 41 19 10.0 172.0 37.3 3 1 More Nore 11.6 2000 10 Hermits 10 Hermits 10 Hermits 10 10 Hermits 10 10 Hermits 10 10 10 Hermits 10	6	55.8	М	Hepatitis C		3.3	382.0	391.0	635.0	2861.0	4.0		2	None	None	None	4.0	0	Q	Hepatitis C vira infection
32.8 M Hepatitis (41 19 107 174.0 290.0 433.0 35 3.0 1 Mid None None 116 2000 10 Hepatitis (45.3 M Hepatitis (543 0.4 125.0 153.0 172.0 197.0 35 7.0 3 1 None None 84 0 20 Hepatitis (51.2 M FTOHI 29 56 7.0 341.0 57.0 35.1 0.0 172.0 197.0 174.0 None None None 90 200 197 10 100		14	54.2	Μ	Hepatitis C		5.9	94.0			3734.0	3.0		2	None	None	None	10.7	0	10	Hepatitis C vira infectior
	24 453 M Heputits 543 04 120 132 132 100 000 000 000 000 000 20 Haputits C rail 100 200 40 100 200 200 200 100 100 200 100 100 200 100 100 200 100 100 200 100 100 200 100 100 200 100 100 200 100 100 100 100 200 100 100 200 100 100 200 100 100 200 100 2000 200	16*	52.8		Hepatitis C		1.9		174.0		443.0	ς.		1	Mild	None	None	11.6	2000	10	Hepatitis C vira infectior
44.1 M Hepatitis 14.1 M Hepatitis 14.1 M Hepatitis 14.1 24 1580 367.0<	41 M Hepatitis C 141 M Hepatitis C 141 M Hepatitis C 141 M Hepatitis C 141 D Hepatitis C 141 D Hepatitis C 141 D Hepatitis C 141 D 153 Mon POID 253 CoiD CoiD <td>24</td> <td>45.3</td> <td>М</td> <td>Hepatitis C</td> <td></td> <td>0.4</td> <td>125.0</td> <td>153.0</td> <td></td> <td>197.0</td> <td></td> <td></td> <td>с</td> <td>1</td> <td>None</td> <td>None</td> <td>8.4</td> <td>0</td> <td>20</td> <td>Hepatitis C vira infectior</td>	24	45.3	М	Hepatitis C		0.4	125.0	153.0		197.0			с	1	None	None	8.4	0	20	Hepatitis C vira infectior
31.2 M ETOH 29 5.6 57.0 72.0 605.0 -4 55.0 0 0 None None 3.6 2000 40 Bile duct 46.0 K ETOH 37 1.5 46.0 570.0 0.5 3.5 0.0 0 None None 0.0 1000 15 Neur 46.0 K K K K K K K None None K	312 M Errol 36 56 57 30 56 30 56 30 <th< td=""><td>41</td><td>44.1</td><td>Μ</td><td>Hepatitis C</td><td>141</td><td>2.4</td><td>159.0</td><td></td><td></td><td>637.0</td><td></td><td></td><td>0</td><td>None</td><td>None</td><td>None</td><td>9.0</td><td>2000</td><td>20</td><td>Hepatitis C vira infectior</td></th<>	41	44.1	Μ	Hepatitis C	141	2.4	159.0			637.0			0	None	None	None	9.0	2000	20	Hepatitis C vira infectior
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	43 75 M ETOH 7 15 440 700 100 100 15 Number solution 45 65.1 M ETOH 67 15 440 700 100 15 Number solution 45 65.1 M ETOH 180 0.5 303.0 374.0 570.0 102.0 50.0 000 000 000 100 15 Number solution 66 M Hepatitis C 23 0.00 6.0 None None 0.0 0.00 100 15 Number solution 10 4.05 10.0 4.0 10.0 0.0 None None <th< td=""><td>42^{\dagger}</td><td>51.2</td><td></td><td>ETOH</td><td></td><td>5.6</td><td>57.0</td><td></td><td></td><td> </td><td>3.5</td><td></td><td>0</td><td>5%</td><td>None</td><td>None</td><td>3.6</td><td>2000</td><td>40</td><td>Bile duct strictur</td></th<>	42^{\dagger}	51.2		ETOH		5.6	57.0				3.5		0	5%	None	None	3.6	2000	40	Bile duct strictur
451 M FTOH 180 0.5 $3.3.0$ $3.4.1$ 0.00 0.5 0.00 0.0 0.00 <	$\vec{4}$ \vec{M} \vec{T} \vec{M}	43 45	75.8 46.0		ETOH		1.5	446.0 77.0		10	45.0			0 0		None Jarked	None None	0.0	1000	15	Neurotoxicity Had TTP
56.6 M Hepatitis L 23 10.9 71.0 82.0 281.0 333.0 3.0 0.0 5 None None 6.9 1000 10 44.5 F ETOH 18 10.5 92.0 106.0 586.0 387.0 3.0 0.0 0 None None 9.6 2000 20 40.5 M Hepatitis C 13 2.7 10.0 64.0 101.0 - 4.0 None None None 9.6 2000 20 32.7 M Hepatitis C 149 8.6 179 795.0 682.0 3.0 0.0 None None None 6.9 0.0 20 20 200 20	56 M Hepatitis C 23 103 71.0 82.0 38.0 30 00 5 None 6.9 1000 10 Hepatitis C 70 44.5 F F70H 18 10.5 32.0 06.0 56.0 35.0 36.0 0.0 None 5.2 2000 20 Hepatitis C rain interconstant 75 32.8 M Hepatitis C 19 30 730 0.0 None None 5.2 2000 20 Hepatitis C rain interconstant 115 32.7 M Hepatitis C 149 8.1 12.0 62.0 30 0.0 None None 9.0 Hepatitis C rain interconstant 116 53.1 M Hepatitis C 296 0.7 19.0 35.0 20.0 0.0 None 9.0 0.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 None None 9.0	48	45.1	Μ	ETOH		0.5	303.0			1028.0			0		None	None	3.4	1000	ŝ	Baseline medication changed
44.5 F FTOH 18 10.5 92.0 106.0 586.0 387.0 3.0 0.0 0 None None 9.6 2000 20 40.5 M Hepatitis C 13 2.7 10.0 64.0 101.0 $-$ 4.0 0.0 0 None None 9.6 2000 20 52.8 F Autoimmune 166 0.6 99 179 208 85.0 3.0 0.0 0 None None 9.6 2000 20 20 32.7 M Hepatitis C 149 8.6 115.0 240.0 795.0 682.0 3.0 0.0 0 None None None 9.5 2000 20 33.1 M Hepatitis C 296 0.7 101.0 162.0 122.0 286.0 3.0 0.0 0 None None 9.6 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 <t< td=""><td>6044.5FETOH1810.59.00.06.00NoneNone9.62000200Bilary Statestant7740.5MHepatitis C132.710.064.010.1.0-400.0NoneNone5.2200020Hepatitis C traite7732.7MHepatitis C132.710.064.010.1.0-400.0NoneNone8.53.00NoneNone8.53.010.111.332.7MHepatitis C1498.613.0122.0-3.00.0NoneNoneNone9.5Chalultis with fore?11.132.1MHepatitis C1490.719.055.03.00.0NoneNoneNoneNone9.5Chalultis with fore?11.153.1MHepatitis C2480.719.055.0122.0-3.00.0NoneNoneNone9.5Chalultis Cvalutis11.160.5MHepatitis C73.00.5247.03.00.0NoneNoneNone9.51.61.610.1760.2MHepatitis C73.00.53.00.00.0NoneNone7.003.0Hepatitis Cvalutin10.1760.2MHepatitis C73.00.53.00.00.011.00010.1<t< td=""><td>56</td><td>56.6</td><td>Μ</td><td>Hepatitis C</td><td></td><td>10.9</td><td>71.0</td><td></td><td>281.0</td><td></td><td></td><td></td><td>Ŋ</td><td>None</td><td>None</td><td>None</td><td>6.9</td><td>1000</td><td>10</td><td>Hepatitis (</td></t<></td></t<>	6044.5FETOH1810.59.00.06.00NoneNone9.62000200Bilary Statestant7740.5MHepatitis C132.710.064.010.1.0-400.0NoneNone5.2200020Hepatitis C traite7732.7MHepatitis C132.710.064.010.1.0-400.0NoneNone8.53.00NoneNone8.53.010.111.332.7MHepatitis C1498.613.0122.0-3.00.0NoneNoneNone9.5Chalultis with fore?11.132.1MHepatitis C1490.719.055.03.00.0NoneNoneNoneNone9.5Chalultis with fore?11.153.1MHepatitis C2480.719.055.0122.0-3.00.0NoneNoneNone9.5Chalultis Cvalutis11.160.5MHepatitis C73.00.5247.03.00.0NoneNoneNone9.51.61.610.1760.2MHepatitis C73.00.53.00.00.0NoneNone7.003.0Hepatitis Cvalutin10.1760.2MHepatitis C73.00.53.00.00.011.00010.1 <t< td=""><td>56</td><td>56.6</td><td>Μ</td><td>Hepatitis C</td><td></td><td>10.9</td><td>71.0</td><td></td><td>281.0</td><td></td><td></td><td></td><td>Ŋ</td><td>None</td><td>None</td><td>None</td><td>6.9</td><td>1000</td><td>10</td><td>Hepatitis (</td></t<>	56	56.6	Μ	Hepatitis C		10.9	71.0		281.0				Ŋ	None	None	None	6.9	1000	10	Hepatitis (
40.5 M Hepatitis C 13 2.7 10.0 64.0 101.0 $ 4.0$ None None None 5.2 2000 20 20 52.8 F Autoimmune 166 0.6 99 179 208 85.0 3.0 0.0 0 None None 8.5 0.0 20 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	60	44.5		ETOH		10.5	92.0	Г		387.0			0	None	None	None	9.6	2000	20	Biliary abscess
52.8 F Autoimmue 166 0.6 99 179 208 85.0 3.0 0.0 <t< td=""><td>1552.8F Antoinnume1660.60.917920885.03.00.0NoneNone8.505Cellulits with feeral1133.2.7MHepatitis C1498.611.50240.0795.0682.03.00NoneNoneNoneNone1.005Cellulits with feeral11653.1MHepatitis C2480.7101.0162.0122.0-3.52.00NoneNoneNone1.1005Hepatitis C vial11653.1MHepatitis C2480.719.035.0286.0-3.52.00NoneNoneNoneNone10.003.0014.011653.1MHepatitis C2480.719.035.0286.0-3.52.00NoneNoneNoneNoneNone10.0</td><td>70</td><td>40.5</td><td>Μ</td><td>Hepatitis C</td><td>13</td><td>2.7</td><td>10.0</td><td></td><td></td><td>I</td><td>4.0</td><td></td><td>0</td><td>None</td><td>None</td><td>None</td><td>5.2</td><td>2000</td><td>20</td><td>Hepatitis C vira infection + neurotoxicity</td></t<>	1552.8F Antoinnume1660.60.917920885.03.00.0NoneNone8.505Cellulits with feeral1133.2.7MHepatitis C1498.611.50240.0795.0682.03.00NoneNoneNoneNone1.005Cellulits with feeral11653.1MHepatitis C2480.7101.0162.0122.0-3.52.00NoneNoneNone1.1005Hepatitis C vial11653.1MHepatitis C2480.719.035.0286.0-3.52.00NoneNoneNoneNone10.003.0014.011653.1MHepatitis C2480.719.035.0286.0-3.52.00NoneNoneNoneNoneNone10.0	70	40.5	Μ	Hepatitis C	13	2.7	10.0			I	4.0		0	None	None	None	5.2	2000	20	Hepatitis C vira infection + neurotoxicity
32.7 M Hepatitis C 149 8.6 115.0 240.0 795.0 682.0 3.0 2.0 None None $\#$ 2000 20 47.9 M Hepatitis C 296 0.7 101.0 162.0 122.0 - 3.0 5.0 0 None None 11.0 0 5 53.1 M Hepatitis C 248 0.7 19.0 35.0 286.0 - 3.5 2.0 0 None None 11.0 0 5 5 60.6 F PBC 223 0.5 85.0 138.0 367.0 767.0 3.0 0.0 0 Mid None None 8.2 1000 10 10 60.6 F PBC 223 0.5 85.0 138.0 367.0 767.0 3.0 0.0 0 None None 8.2 1000 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	113 32.7 M Hepatitis (14) 46 metric (14) 86 115.0 240.0 795.0 682.0 3.0 2.0 None None None $-\#$ 2000 20 Hepatitis (Vial Miccion 11) 4.7.9 M Hepatitis (296 0.7 101.0 162.0 122.0 - 3.0 5.0 0 None None None 11.0 0 5 Hepatitis (Vial Miccion 11) 6.6.6 F PBC 223 0.5 85.0 135.0 286.0 - 3.5 2.0 0 None None None 11.0 0 5 Hepatitis (Vial Miccion 11) 6.6.1 F PBC 223 0.5 85.0 135.0 286.0 - 3.5 2.0 0 Mid None None 8.2 1000 10 Bla duct stincture IDLT 6.0.2 M Hepatitis (C 233 0.5 767.0 381.0 694.0 3.0 1.5 0 Mid None None 8.2 1000 10 Bla duct stincture IDLT 6.0.2 M Hepatitis (C 233 0.5 767.0 381.0 694.0 3.0 1.5 0 Mid None None 8.2 1000 10 Bla duct stincture 1DLT 6.0.2 M Hepatitis (C 35 0.6 78.0 127.0 381.0 694.0 3.0 1.5 0 Mid None None 8.2 1000 10 Bla duct stincture 1DLT 6.0.2 M Hepatitis (C 77.9 min 7.0 0 1.5 1.4 2.0 1.4 3.0 4.8 1.4 3.0 4.8 1.4 5.0 1.8 1.4 None None 7.0 0 15 Hepatitis (C 71.9 min 80.0 0.0 1.4 1.4 None 1.4 2.0 0.0 1.5 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4	75	52.8	ч Ч	Autoimmune	166	0.6	66		208	85.0			0	None	None	None	8.5	0	ß	Cellulitis with fever
47.9 M Hepatitis C 296 0.7 101.0 162.0 122.0 - 3.0 5.0 0 None None 11.0 0 5 53.1 M Hepatitis C 248 0.7 19.0 35.0 286.0 - 3.5 2.0 0 None None 11.0 0 20 60.6 F PBC 223 0.5 85.0 138.0 367.0 767.0 3.0 0.0 0 Mild None 8.2 1000 10 Bi 60.2 M Hepatitis C 55 0.5 138.0 367.0 767.0 3.0 0.0 0 Mild None 8.2 1000 10 Bi 60.2 M Hepatitis C 55 0.5 138.0 381.0 694.0 3.0 1.5 0 Mild None None 7.0 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	11547.9MHepatitis C296 0.7 10.10 162.0 122.0 2.0 3.0 5.0 $0.0m$ NoneNone 11.0 0 5 Hepatitis C viral infection116 53.1 MHepatitis C 248 0.7 19.0 35.0 286.0 -3.5 2.0 $None$ $None$ $None$ $None$ 0.0 20 Hepatitis C viral infection119 60.6 FPBC 223 0.5 85.0 138.0 367.0 757.0 3.0 0.0 0 $Mild$ $None$ $None$ 0.0 0 20 Hepatitis C viral infection 40 60.2 MHepatitis C 53 0.5 85.0 138.0 367.0 757.0 3.0 0.0 0 $Mild$ $None$ $None$ 0.0 0 20 Hepatitis C viral infection 40 60.2 MHepatitis C 53 0.6 78.0 381.0 694.0 3.0 1.5 0 $Mild$ $None$ <t< td=""><td>113</td><td>32.7</td><td>Μ</td><td></td><td>149</td><td>8.6</td><td>115.0</td><td></td><td></td><td>682.0</td><td></td><td></td><td>0</td><td>None</td><td>None</td><td>None</td><td>#</td><td>2000</td><td>20</td><td>Hepatitis C vira infectior</td></t<>	113	32.7	Μ		149	8.6	115.0			682.0			0	None	None	None	#	2000	20	Hepatitis C vira infectior
53.1 M Hepatitis C 248 0.7 19.0 35.0 286.0 - 3.5 2.0 0 None None 5.9 0 20 60.6 F PBC 223 0.5 85.0 138.0 367.0 767.0 3.0 0.0 0 Mid None 8.2 1000 10 Bi 60.2 M Hepatitis C 55 0.6 78.0 137.0 381.0 694.0 3.0 1.5 0 Mid None 8.2 1000 10 Bi 53.2 F Cryptogenic 93 1.4 33.0 48.0 145.0 118.0 4.0 0.0 0 None None 7.0 0 15 Bas	11653.1MHepatitis C248 0.7 19.035.0286.0 $-$ 3.52.0NoneNone5.9020Hepatitis C viral infection11960.6FPBC2230.585.0138.0367.0767.03.00.0MildNone8.2100010Bile duct stricture infectionLDLT60.2MHepatitis C550.678.0137.0381.0694.03.01.50MildNone8.2100010Hepatitis C viral infection8353.2FCryptogente931.433.048.0145.0118.04.00.0NoneNone7.0015Hepatitis C viral infection8353.2FCryptogente931.433.048.0145.0118.04.00.0NoneNone7.0015Baseline medication changed ¹¹ Case 16 Rad1.433.04.8.0145.0118.04.00.00000000String transferase:ATalmost transplant:L/TNoneNoneNone7.0015Baseline medicationCase 4.0 Rad145.0118.04.00.00NoneNoneNone7.0015Prosplant:CString transferase:ATPaseline transplant:L/T <td>115</td> <td>47.9</td> <td></td> <td></td> <td></td> <td>0.7</td> <td>101.0</td> <td></td> <td></td> <td> </td> <td>3.0</td> <td></td> <td>0</td> <td>None</td> <td>None</td> <td>None</td> <td>11.0</td> <td>0</td> <td>ນ</td> <td>Hepatitis C vira infectior</td>	115	47.9				0.7	101.0				3.0		0	None	None	None	11.0	0	ນ	Hepatitis C vira infectior
60.6 F PBC 223 0.5 85.0 138.0 367.0 767.0 3.0 0.0 0 Mild None 8.2 1000 10 Bi 60.2 M Hepatitis C 55 0.6 78.0 127.0 381.0 694.0 3.0 1.5 0 Mild None -** 2000 15 53.2 F Cryptogenic 93 1.4 33.0 48.0 145.0 118.0 4.0 0.0 0 None None 7.0 0 15 Bas	119 60.6 F PBC 223 0.5 85.0 138.0 367.0 75.0 3.0 0.0 0 Mid None 8.2 1000 10 Bile duct stricture LDLT 60.2 M Hepatitis C 55 0.6 78.0 127.0 38.1.0 694.0 3.0 1.5 0 Mid None -** 2000 15 Hepatitis C viral 83 53.2 F Cryptogenic 93 1.4 33.0 48.0 185.0 18.0 0.0 0 None None -** 2000 15 Baseline medication 83 53.2 F Cryptogenic 93 1.4 33.0 48.0 18.0 18.0 10.0 0 None None 7.0 0 15 Baseline medication 83 53.2 F Cryptogenic 93 1.4 33.0 48.0 18.0 17.0 0 0 15 Baseline medication	116	53.1	Μ	Hepatitis C	248	0.7	19.0		286.0	I	3.5		0	None	None	None	5.9	0	20	Hepatitis C vira infectior
60.2 M Hepatitis C 55 0.6 78.0 127.0 381.0 694.0 3.0 1.5 0 Mild None —** 2000 15 53.2 F Cryptogenic 93 1.4 33.0 48.0 145.0 118.0 4.0 0.0 0 None None 7.0 0 15 Bas	4060.2MHepatitis C550.678.0127.0381.0694.03.01.50MildNone-**200015Hepatitis C viral8353.2FCryptogenic931.433.048.0145.0118.04.00.00NoneNone7.0015Baseline medication8353.2FCryptogenic931.433.048.0145.0118.04.00.00NoneNone7.0015Baseline medicationAbbreviations: Alk PO4, alkaline phosphatase: AJ7. alanine aminotransferase: AS7. aspartate aminotransferase: IDI/T, deceased donor liver transplant: M, male: MMF, mycophenolate moleciti: PBC, primary biliaryAbbreviations: RML rejection activity index: Tacro, tacrolimus: TTP, thrombotic thrombocytopenic purpura.Case 42 had a total of 5 biopsies. The first biopsy was treated with steroids (Table 6); he had persistent bile duct stricture with recurrent cholangitis and did not receive steroid bolus.Case 43 had TP. Tacro was put on hold, and he was switched to cyclosporine A.Case 48. Tacro was put on hold, and he was switched to cyclosporine.For case 45 had TP. Tacro was put on hold, and he was switched to 2000 mg/day, and prediction activity index.Tacro was increased from 0.4. adh the was switched to 1500 mg/day.For case 48. Tacro was increased from 2 to 3 mg twice daily.MMF was increased from 1000 to 2000 mg/day, and predicisolone was increased from 1000 to 2000 mg/day, and predicisolone was increased from 4.0.5 mg/day."For case 40 was on cyclosporine A at a level of 150 mg/MMFAnd the second was	119 1 DI T	60.6	ы	PBC		0.5	85.0			767.0			0	Mild	None	None	8.2	1000	10	Bile duct strictur
53.2 F Cryptogenic 93 1.4 33.0 48.0 145.0 118.0 4.0 0.0 0 None None None 7.0 0 15 Baseline r	83 53.2 F Cryptogenic 93 1.4 33.0 48.0 145.0 118.0 4.0 0.0 0 None None None 7.0 0 15 Baseline medication changed ¹⁴ Abbreviations: Alk PO4, alkaline phosphatase: AJT, alamine aminotransferase: AST, aspartate aminotransferase: DDLT, deceased donor liver transplant: ETOH, alcohol-induced cirrhosis: F induced GTP, gamma glutamyl transpeptidase; HAI, hepatitis activity index: LDLT, live donor liver transplant: LTX. liver transplant: M, male: MMF, mycophenolate mofetil; PBC, primary biliary irrhosis: RAI, rejection activity index: Tacro, tacrolinuus; TTP, thrombotic thrombocytopenic purpura. Case 42 had a total of 5 biopsies. The first biopsy was treated with steroids (Table 6); he had persistent bile duct stricture with recurrent cholangitis and did not receive steroid bolus. For case 43. Tacro was put on hold, and he was switched to cyclosporine A. For case 43. Tacro was put on hold, and he was switched to cyclosporine A. For case 45 had TTP. Tacro was put on hold, and he was given intravenous immunoglobulin. For case 45 had TTP. Tacro was put on hold, and he was given intravenous immunoglobulin. For case 45 the Tacro dose was increased from 4 to 5 mg twice daily. For case 75, the Tacro dose was increased from 4 to 5 mg twice daily. Case 40 was on cyclosporine A at a level of 159 mg/mL.	40	60.2	Μ			0.6	78.0			694.0			0	Mild	Mild	None	*	2000	15	Hepatitis C vira infectior
	Abbreviations: Alk PO4, alkaline phosphatase: ALT, alanine aminotransferase: AST, aspartate aminotransferase: DDLT, deceased donor liver transplant; ETOH, alcohol-induced cirrhosis; F irrhosis; RAI, rejection activity index; Tacro, tacrolimus; TTP, thrombotic thrombocytopenic purpura. Case 16 had 2 biopsies. The first biopsy was treated with steroids (Table 6); he had persistent bile duct stricture with recurrent cholangitis and did not receive steroid bolus. For case 42 had a total of 5 biopsies. The first biopsy was treated with steroids (Table 6); he had persistent bile duct stricture with recurrent cholangitis and did not receive steroid bolus. For case 43, Tacro was put on hold, and he was switched to cyclosporine A. Case 45 had TTP. Tacro was put on hold, and he was given intravenous immunoglobulin. For case 43, Tacro was put on hold, and he was given intravenous immunoglobulin. Case 45 had TTP. Tacro was put on hold, and he was given intravenous immunoglobulin. For case 43, Tacro was put on hold, and he was given intravenous immunoglobulin. Gase 45 had TTP. Tacro was necessed from 4 to 5 mg twice daily. For case 75, the Tacro was increased from 4 to 5 mg twice daily. For case 75, the Tacro dose was increased from 4 to 5 mg twice daily. Case 40 was on cyclosporine A at a level of 159 mg/mL.	83	53.2	ц			1.4	33.0		145.0				0	None	None	None	7.0	0	15	Baseline medicatior changed⁺
		#Case	113 had 40 was	2 biof on cyc	losporine A a	t was treated t a level of 1	d (Table 6), 159 ng/mL.	and u	le seco.	nd was no	t treated	l. The	patien.	t was o	n cyclos	porine A	at a level	of 160 ng/	/mL.		

Interpretational librition Interpretation Interpr	Immunosuppression at the Time Treatment of of of Tacro of Rejection: of Rejection: of Tacro of Rejection: Respection: Respection: $rig/main Immunosuppression at the Time Respection: Respection: Respection: rig/main Img/day Img/day Img/day Prechisione Respection: rig/main Img/day Img/day Img/day Prechisione Respection: rig/main Img/day Img/day Img/day Prechisione Respective: rig/main Img/day Img/day Respective: Respective: Respective: rig/main Img/day Img/day Img/day None Replications rig/main Img/day Img/day Img/day Replications Img/day rig/main Img/day Img/day Img/day Replications Replications rig/main Img/day Img/day Img/day Replications Img/da$	International distributional distributi distributi di distributional di distributica distributional dis	Liver Function Days Liver Function Lix Biltrubin AST ALT tion (mg/dl) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 113 20.9 39 97 114 20.9 39 97 112 0.6 275 500 113 20.9 39 97 114 1.2 447 542 143 1.2 447 542 143 1.2 447 542 143 1.3 195 412 217 1.3 195 412 7.3 150.12 7.173.3 135 217 1.41.173 1.50.51 308.1 7.3 1.51.2 2.17.1	The transmised of t								TA	BLE	5. De	tails	01 AC	ute ke	jectioi	Details of Acute Rejection and Management	nagemei	nt								
Alt Interfacient	Interfaction Interfaction<	Independence Independence<	Liver Function Days Liver Function Lix Bilirubin AST ALT tion (mg/dl) (n/1) (n/1) (n/1) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 113 20.9 39 97 114 20.9 39 97 112 0.6 275 500 113 20.9 34 542 114 1.2 447 542 143 1.2 447 542 143 1.3 135 412 217 1.3 135 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5	I.Iver Functo Jays I.Iver Functo I.Tx Biltrubin AST ALT tion (mg/dl) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 113 20.9 34 78 114 20.9 39 97 112 6.2 276 500 124 5.7 100 113 124 5.7 100 113 124 5.7 100 113 217 1.2 447 542 129 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1																	Immunosı	uppression	at the Time	Treatment					
$ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	Interpretation And TA province And TA prov	Norm Norm <th< th=""><th>Days Days LTX Biltrubin AST ALT tion (mg/dL) (u/L) (u/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 113 9.6 78 341 114 1.2.8 88 341 12 6.2 447 542 143 1.2 447 542 143 1.2 447 542 15 5.7 100 113 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.1 7.173.3 ata moffetti: RAL RAL atamine antin ata moffetti: RAL ransepotion atamine antion</th><th>Days Days LTX Bilirubin AST ALT tion (mg/dL) (u/L) (u/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 113 9.6 78 341 53 12.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 13 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptidate amin ataseptidate amin atase: ALT, alamine amin atase atase atase TOH. atase atase</th><th></th><th></th><th></th><th></th><th>I</th><th></th><th>Liver]</th><th>Functio</th><th>uc</th><th></th><th></th><th></th><th></th><th></th><th>Biopsy</th><th>Findings</th><th></th><th>1</th><th>of Rejection</th><th>of</th><th></th><th></th></th<>	Days Days LTX Biltrubin AST ALT tion (mg/dL) (u/L) (u/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 113 9.6 78 341 114 1.2.8 88 341 12 6.2 447 542 143 1.2 447 542 143 1.2 447 542 15 5.7 100 113 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.1 7.173.3 ata moffetti: RAL RAL atamine antin ata moffetti: RAL ransepotion atamine antion	Days Days LTX Bilirubin AST ALT tion (mg/dL) (u/L) (u/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 113 9.6 78 341 53 12.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 13 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptidate amin ataseptidate amin atase: ALT, alamine amin atase atase atase TOH. atase atase					I		Liver]	Functio	uc						Biopsy	Findings		1	of Rejection	of					
App Table Transmissione Descriptione Descriptione <th>orie More Tender Tender More More</th> <th>offer offer <th< th=""><th>LTx Biltrubin AST ALT tion (mg/dL) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 11 20.9 39 341 53 12.8 88 341 12 5.7 100 113 34 5.7 100 113 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 30.5 30.5</th><th>LTx Bilirubin AST ALT tion (mg/dL) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 111 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 ataase: ALT, alamine amin ataaseptida amin atase and transpeptida amin atase: ALT, alamine amin atase ALT. atase ALT. alamine amin atase ALT. alamine amin atase ALT. alamine amin atase ALT. alamine amin <t< th=""><th></th><th></th><th></th><th></th><th>Days</th><th></th><th></th><th></th><th>Alk</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>Tacro</th><th></th><th></th><th>Rejection:</th><th></th><th></th></t<></th></th<></th>	orie More Tender Tender More	offer offer <th< th=""><th>LTx Biltrubin AST ALT tion (mg/dL) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 11 20.9 39 341 53 12.8 88 341 12 5.7 100 113 34 5.7 100 113 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 30.5 30.5</th><th>LTx Bilirubin AST ALT tion (mg/dL) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 111 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 ataase: ALT, alamine amin ataaseptida amin atase and transpeptida amin atase: ALT, alamine amin atase ALT. atase ALT. alamine amin atase ALT. alamine amin atase ALT. alamine amin atase ALT. alamine amin <t< th=""><th></th><th></th><th></th><th></th><th>Days</th><th></th><th></th><th></th><th>Alk</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>Tacro</th><th></th><th></th><th>Rejection:</th><th></th><th></th></t<></th></th<>	LTx Biltrubin AST ALT tion (mg/dL) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 11 20.9 39 341 53 12.8 88 341 12 5.7 100 113 34 5.7 100 113 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.3 150.5 30.5 30.5	LTx Bilirubin AST ALT tion (mg/dL) (n/L) (n/L) 10 9.3 40 78 11 20.9 39 97 111 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 ataase: ALT, alamine amin ataaseptida amin atase and transpeptida amin atase: ALT, alamine amin atase ALT. atase ALT. alamine amin atase ALT. alamine amin atase ALT. alamine amin atase ALT. alamine amin <t< th=""><th></th><th></th><th></th><th></th><th>Days</th><th></th><th></th><th></th><th>Alk</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>Tacro</th><th></th><th></th><th>Rejection:</th><th></th><th></th></t<>					Days				Alk								Tacro			Rejection:					
Matrix Matrix <th matrix<="" th=""> <th matrix<="" th=""> <th matrix<<="" th=""><th>Control MP France Rate Recent random (multi lar) (LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1</th><th>Image: index weight in the index of index weight in the index weight inde</th><th>ition (mg/dl) (u/l) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 113 9.6 275 500 114 1.2.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 73.3 ataase: ALT, alarine amin ataasee amin ata mg/ttamspeptid at mofetti: RAI, respectid at and at mofetti: RAI, respectid at and at a mofetti: RAI, respectid at and at a mofetti: RAI, respectid at a mofetti: RAI, respectid at a mofetti at a mofetti</th><th>ition (mg/dl) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 12 4.47 542 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3. attase: ALT, alamine amin attase; ML, alamine amin attase; ML, alamine amin attase: ALT, alamine amin attase; ML, rejection attase; ML, rejection attase; ML attase; ML attase; ALD, and ETOH. attase; ML attase; ML attase; ML </th><th></th><th>Age</th><th></th><th></th><th></th><th>Bilirubin</th><th></th><th>ALT</th><th>P04</th><th>GGTP</th><th></th><th></th><th></th><th></th><th>, ,</th><th>Ischemic</th><th>Level</th><th></th><th>Б</th><th>Methyl</th><th>Associated</th><th></th></th></th></th>	<th matrix<="" th=""> <th matrix<<="" th=""><th>Control MP France Rate Recent random (multi lar) (LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1</th><th>Image: index weight in the index of index weight in the index weight inde</th><th>ition (mg/dl) (u/l) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 113 9.6 275 500 114 1.2.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 73.3 ataase: ALT, alarine amin ataasee amin ata mg/ttamspeptid at mofetti: RAI, respectid at and at mofetti: RAI, respectid at and at a mofetti: RAI, respectid at and at a mofetti: RAI, respectid at a mofetti: RAI, respectid at a mofetti at a mofetti</th><th>ition (mg/dl) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 12 4.47 542 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3. attase: ALT, alamine amin attase; ML, alamine amin attase; ML, alamine amin attase: ALT, alamine amin attase; ML, rejection attase; ML, rejection attase; ML attase; ML attase; ALD, and ETOH. attase; ML attase; ML attase; ML </th><th></th><th>Age</th><th></th><th></th><th></th><th>Bilirubin</th><th></th><th>ALT</th><th>P04</th><th>GGTP</th><th></th><th></th><th></th><th></th><th>, ,</th><th>Ischemic</th><th>Level</th><th></th><th>Б</th><th>Methyl</th><th>Associated</th><th></th></th></th>	<th matrix<<="" th=""><th>Control MP France Rate Recent random (multi lar) (LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1</th><th>Image: index weight in the index of index weight in the index weight inde</th><th>ition (mg/dl) (u/l) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 113 9.6 275 500 114 1.2.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 73.3 ataase: ALT, alarine amin ataasee amin ata mg/ttamspeptid at mofetti: RAI, respectid at and at mofetti: RAI, respectid at and at a mofetti: RAI, respectid at and at a mofetti: RAI, respectid at a mofetti: RAI, respectid at a mofetti at a mofetti</th><th>ition (mg/dl) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 12 4.47 542 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3. attase: ALT, alamine amin attase; ML, alamine amin attase; ML, alamine amin attase: ALT, alamine amin attase; ML, rejection attase; ML, rejection attase; ML attase; ML attase; ALD, and ETOH. attase; ML attase; ML attase; ML </th><th></th><th>Age</th><th></th><th></th><th></th><th>Bilirubin</th><th></th><th>ALT</th><th>P04</th><th>GGTP</th><th></th><th></th><th></th><th></th><th>, ,</th><th>Ischemic</th><th>Level</th><th></th><th>Б</th><th>Methyl</th><th>Associated</th><th></th></th>	<th>Control MP France Rate Recent random (multi lar) (LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1</th> <th>Image: index weight in the index of index weight in the index weight inde</th> <th>ition (mg/dl) (u/l) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 113 9.6 275 500 114 1.2.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 73.3 ataase: ALT, alarine amin ataasee amin ata mg/ttamspeptid at mofetti: RAI, respectid at and at mofetti: RAI, respectid at and at a mofetti: RAI, respectid at and at a mofetti: RAI, respectid at a mofetti: RAI, respectid at a mofetti at a mofetti</th> <th>ition (mg/dl) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 12 4.47 542 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3. attase: ALT, alamine amin attase; ML, alamine amin attase; ML, alamine amin attase: ALT, alamine amin attase; ML, rejection attase; ML, rejection attase; ML attase; ML attase; ALD, and ETOH. attase; ML attase; ML attase; ML </th> <th></th> <th>Age</th> <th></th> <th></th> <th></th> <th>Bilirubin</th> <th></th> <th>ALT</th> <th>P04</th> <th>GGTP</th> <th></th> <th></th> <th></th> <th></th> <th>, ,</th> <th>Ischemic</th> <th>Level</th> <th></th> <th>Б</th> <th>Methyl</th> <th>Associated</th> <th></th>	Control MP France Rate Recent random (multi lar) (LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1 LU1	Image: index weight in the index of index weight in the index weight inde	ition (mg/dl) (u/l) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 113 9.6 275 500 114 1.2.8 88 341 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 73.3 ataase: ALT, alarine amin ataasee amin ata mg/ttamspeptid at mofetti: RAI, respectid at and at mofetti: RAI, respectid at and at a mofetti: RAI, respectid at and at a mofetti: RAI, respectid at a mofetti: RAI, respectid at a mofetti	ition (mg/dl) (u/l) (u/l) 10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 113 12.8 88 341 12 4.47 542 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3. attase: ALT, alamine amin attase; ML, alamine amin attase; ML, alamine amin attase: ALT, alamine amin attase; ML, rejection attase; ML, rejection attase; ML attase; ML attase; ALD, and ETOH. attase; ML attase; ML attase; ML		Age				Bilirubin		ALT	P04	GGTP					, ,	Ischemic	Level		Б	Methyl	Associated	
	30731 <th>3. 3. 1 1 4. 1 4</th> <th>10 9.3 40 78 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 12 0.6 275 500 13 12.8 88 341 143 1.2 447 542 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 ataase: ALT, alarine amin ataase: ALT, alarine amin ataase: ALT, alarine amin ata ata 015. 7.3 150.17 713.3 016. 141. 201.7 173.3 </th> <th>10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 12 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 12 6.2 20 67 13 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin atase: ALT, alamine amin atase; ALT, alamine amin ma glutamyl transpeptidate amin atase; ALM, rejection at and attase; AM, rejection at and attase; AM, rejection at and attase; AM, rejection at a and attase; AM, rejectio</th> <th></th> <th>Years)</th> <th>M/F Pr</th> <th>imary Diagnosis</th> <th>Rejection</th> <th>(mg/dL)</th> <th>(1/I)</th> <th>(n/L)</th> <th>(n/L)</th> <th>(n/L)</th> <th>RAI H</th> <th>AI Fibi</th> <th>rosis Ste</th> <th>atosis C</th> <th>Cholestasis</th> <th>Injury</th> <th>(ng/mL)</th> <th>(mg/day)</th> <th>(mg/day)</th> <th>Prednisone</th> <th>Risk Factors</th> <th>Outcome</th>	3. 3. 1 1 4. 1 4	10 9.3 40 78 11 20.9 39 97 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 112 0.6 275 500 12 0.6 275 500 13 12.8 88 341 143 1.2 447 542 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 ataase: ALT, alarine amin ataase: ALT, alarine amin ataase: ALT, alarine amin ata ata 015. 7.3 150.17 713.3 016. 141. 201.7 173.3	10 9.3 40 78 11 20.9 39 97 11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 12 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 12 6.2 20 67 13 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin atase: ALT, alamine amin atase; ALT, alamine amin ma glutamyl transpeptidate amin atase; ALM, rejection at and attase; AM, rejection at and attase; AM, rejection at and attase; AM, rejection at a and attase; AM, rejectio		Years)	M/F Pr	imary Diagnosis	Rejection	(mg/dL)	(1/I)	(n/L)	(n/L)	(n/L)	RAI H	AI Fibi	rosis Ste	atosis C	Cholestasis	Injury	(ng/mL)	(mg/day)	(mg/day)	Prednisone	Risk Factors	Outcome			
451 M = 470 111 20.9 37 4000<	1 1	1 1 1 200 30 <td>11 20.9 39 97 112 0.6 275 500 53 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 ataase: ALT, alamine amin ataaseeptida ata ata ata moffetti: RAI, respectidn da onis onis onis</td> <td>11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 13 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin ma glutamyl transpeptidate amin atase; ALH. atase; ALH. ons.ud ETOH. ons.ud ETOH. ons.ud</td> <td>DLT</td> <td>51.2</td> <td>М</td> <td>Laennec's</td> <td></td> <td>9.3</td> <td></td> <td></td> <td>106</td> <td>136</td> <td>9</td> <td>0</td> <td>0</td> <td>7%</td> <td>I</td> <td>l</td> <td>5.9</td> <td>1000</td> <td>сı</td> <td>750 mg</td> <td></td> <td>Responded</td>	11 20.9 39 97 112 0.6 275 500 53 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 ataase: ALT, alamine amin ataaseeptida ata ata ata moffetti: RAI, respectidn da onis onis onis	11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 13 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin ma glutamyl transpeptidate amin atase; ALH. atase; ALH. ons.ud ETOH. ons.ud ETOH. ons.ud	DLT	51.2	М	Laennec's		9.3			106	136	9	0	0	7%	I	l	5.9	1000	сı	750 mg		Responded			
45 M HCV and ETOH 11 203 97 200 20 200 20 200 </td <td>457 M HOV and ETOH 11 203 37 364 Ten one Ten one and M HOV and ETOH 11 203 37 37 30 79.01 Ten one and M HOV and ETOH 11 203 361 31 3</td> <td></td> <td>11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 143 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3. atase: ALT, alamine amin ataseptidia ate mofetil: RAI, rejection atoms ons. and ETOH. ata CIOH. ataseptidia</td> <td>11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 13 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amine am</td> <td></td> <td>over 3</td> <td></td> <td></td>	457 M HOV and ETOH 11 203 37 364 Ten one Ten one and M HOV and ETOH 11 203 37 37 30 79.01 Ten one and M HOV and ETOH 11 203 361 31 3		11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 143 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3. atase: ALT, alamine amin ataseptidia ate mofetil: RAI, rejection atoms ons. and ETOH. ata CIOH. ataseptidia	11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 13 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amine am																				over 3					
	67 10 10 10 20 30 10 100 20 <t< td=""><td>57 10 <td< td=""><td>11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 124 1.3 195 412 7.0 148.1 201.7 173.3 134 148.1 201.7 173.3 1438 148.1 201.7 173.3 1438 148.1 201.7 173.3 1438 148.1 201.7 173.3 144 148.1</td><td>11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida te mofetti. RAI, rejection to ani anis atase: ALT, alamine amin atase and FTOH. atase</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>days</td><td>Та</td><td></td></td<></td></t<>	57 10 <td< td=""><td>11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 124 1.3 195 412 7.0 148.1 201.7 173.3 134 148.1 201.7 173.3 1438 148.1 201.7 173.3 1438 148.1 201.7 173.3 1438 148.1 201.7 173.3 144 148.1</td><td>11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida te mofetti. RAI, rejection to ani anis atase: ALT, alamine amin atase and FTOH. atase</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>days</td><td>Та</td><td></td></td<>	11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 124 1.3 195 412 7.0 148.1 201.7 173.3 134 148.1 201.7 173.3 1438 148.1 201.7 173.3 1438 148.1 201.7 173.3 1438 148.1 201.7 173.3 144 148.1	11 20.9 39 97 112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida te mofetti. RAI, rejection to ani anis atase: ALT, alamine amin atase and FTOH. atase																				days	Та				
64 64	0 0	• 053 b M Hanohandus Latron 112 b 056 b 231 b 000 b	112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alarine amin and glutamyl transpeptidate amin and glutamyl transpection tag atase: ALT, alarine amin amin amin and glutamyl transpection tag atase: ALT, alarine amin amin amin amin amin amin amin amin	112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 12 6.2 20 67 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin adition alution and alutanyl transpeptidate to mofetti: RAI, rejection a ons. ons.		45.7	Μ	HCV and ETOH		20.9			247	398	4	0	0	I	moderate r	noderate	5.9	2000	20	750 mg		Responded			
65 M Hanchmanus 11 0.6 275 501 31 0 70	• 68.9 II Heurodromatores 11 0.6 7.5 0.0 7.5 0.0 7.5 0.0 7.5 0.0 0.0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 7.5 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0.00 0 0.00 0 0.00 0 0.00 </td <td>0 0 Hureelementes 10 0 <</td> <td>112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin atasepetidia atasepetidia atase: ALT, alamine amin atasepetidia atasepetidia ataser and ETOH. atasepetidia atasepetidia</td> <td>112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptidate amin attase attase: ALT, alamine amin attase attase attase attase 7.0 148.1 201.7 173.3 attase ALT, alamine amin attase attase attase attase ALT, alamine amin attase attase attase attase ALT. alamine amin attase attase attase TOH.</td> <td></td> <td>over 3</td> <td></td> <td></td>	0 0 Hureelementes 10 0 <	112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin atasepetidia atasepetidia atase: ALT, alamine amin atasepetidia atasepetidia ataser and ETOH. atasepetidia atasepetidia	112 0.6 275 500 53 12.8 88 341 53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptidate amin attase attase: ALT, alamine amin attase attase attase attase 7.0 148.1 201.7 173.3 attase ALT, alamine amin attase attase attase attase ALT, alamine amin attase attase attase attase ALT. alamine amin attase attase attase TOH.																				over 3					
and ErOH	and ETOH	Image: independent of the set of	53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidation a glutamyl transpectidon a glutamyl transpectido	53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida atase autorul transpetida ani atase autorul ani	*	68.9	Μ	emochromatosis		0.6				294	n	0	0	I			3.5 2	1000	0	days 750 mg		Responded			
	$ \ \ \ \ \ \ \ \ \ \ \ \ \ $	¹ 570 M HCV and ETOH is 128 83 11.26 93 12.05 59 75 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidation a glutamyl transpeptidate a min and glutamyl transpectidate a glutamyl transpectidate a min and glutamyl transpectidate a min and glutamyl transpectidate a glutamyl tr	53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida atase; ALT, alamine amin ma glutamyl transpeptida anis atase; ALT, alamine amin atase: ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase: ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin atase; ALT, alamine amin				and ETOH																over 3	comp	T			
570 M HCV and ETOH 53 128 58 51 56 1000 150.00 150.00 Non- 41 M HCV and ETOH 34 57 100 130.00 100	$ \ \ \ \ \ \ \ \ \ \ \ \ \ $	$ \begin{bmatrix} 57.0 & M & HCV and ETOH \\ 57.0 & M & HCV and ETOH \\ 58 & 128 & 58 & 71 & 50 \\ 58 & 57 & 50 & 128 \\ 58 & 51 & 52 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51 & 51 \\ 51 & 52 \\ 51 & 51 \\ 51$	53 12.8 88 341 34 5.7 100 113 143 1.2 447 542 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin and glutamyl transpeptida te mofetti! RAI, rejection á ons. ons.	53 12.8 88 341 34 5.7 100 113 34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida ani atase: ALT, alamine amin ataseptida anis atase: ALT, alamine amin anis atase atase atase atron of transpeptida anis atase atase atase atron atase atase atase atase TOH. atase atase atase																				days	for				
31.1 Moderation 0.0 1.0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \left \begin{array}{cccccccccccccccccccccccccccccccccccc$	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidate amin and glutamyl transpection and glutamyl	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: AUT, alamine amin ma glutamyl transpeptidate mofethi: RAI, rejection atom soms and ETOH.	+	57.0		HCV and ETOH		12.8			206		5	0	C	I	I	I	с С	1000	01	1500 mg	medications, Non-	Resnanded			
	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	9 494 M HCV and ETOH 34 5.7 100 113 551 172 5 0 3006 moderate 405 730 moderate moderat moderat moderat	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptidia ataset: ALT, alamine amin ataseptidia	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin attaseptida attase attase: ALT, alamine amin attaseptida attase attase: ALT, alamine amin attase attase ons and ETOH. ons and ETOH. ons		2									2	>	þ				5	0001	21	Sur coor	non	mindent			
431 M HCV and ETOH 34 57 100 113 561 172 5 2 0 306 moderate - 4 0 10 75 mg and ETOH 34 57 100 113 551 172 5 2 0 306 moderate - 4 0 10 750 mg Secrete and ETOH 327 M MCV 143 541 53 32 0 306 moderate - - 4 0 10 750 mg Secrete	$ 1.3 \ 1.3$	3 434 M HCV and ETOH 34 57 100 113 51 173 50 30% modeate - 4 0 7 70M Server Balance 3 32.7 M HCV and ETOH 34 53 17 17 50 70 m Server	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidate amin and a glutamyl transpeptidate amin and glutamyl transpeptidate amin and soms. at a soms.	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 tatase: ALT, alamine amin tatase: ALT, alamine amin at apoliticanyl transpeptidate tatase: ALT, alamine amin at apoliticanyl transpeptidate tatase: ALT, alamine amin at apoliticanyl transpeptidate tots and ETOH.																				days	combine				
	0 49.4 M HCV and ETOH 34 5.7 100 112 551 172 5 0 30% moderate - 4 0 10 750 ms Servers Delayed 1 32.7 M HCV and ETOH 34 5.1 172 5 0 30% moderate - 4 0 10 750 ms servers moderate 1 32.7 M HCV 143 542 388 20 0 0 0 0 10 790 ms servicus ser	$ \left $	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3.3 at a glutamyl transpeptidation a glutamyl transpectidation a glutamyl transpecidation a glutamyl transpectida	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atlasse: ALT, alamine amin atlamine amin atlasseptida ma glutamyl transpeptida atlasse amin atlasseptida atlasse: ALT, alamine amin atlasseptida atlasseptida atlasse and ETOH. atlasse atlasse																				2					
49.4 M HCV and ETOH 34 5.7 100 113 551 172 5 2 0 30% moderate - 4 0 10 750 mg servers 32.7 M HCV and ETOH 14 5.7 100 113 51 172 5 2 0 30% moderate - 4 0 10 750 mg servers ser	0 494 M HCV and ETOH 34 57 100 113 511 172 5 2 0 30% moderate - 4 0 10 750 mg server Delayed 3 32.7 M HCV and ETOH 34 5.7 100 113 511 72 5 0 0 0 0 100 700 mg server acroses 3 32.7 M HCV 143 12 447 542 385 229 5 0 0 0 0 100 mg server acroses	3 34.4 M HCV and ETOH 34 57 100 113 551 172 5 2 0006 moderate - 4 0 10 75 mm Server Delayed 3 32.7 M HCV 143 12 447 542 58 22 0 0 0 10 75 mm Server 400 7 webs 3 32.7 M HCV 143 12 447 542 58 22 0 0 0 10 700 mg 50 50 50 50 0 0 0 10 100 mg 50 50 50 50 50 50 50 50 50 50 50 60 0 0 10 100 mg 50 50 60 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3.3 nat aglutamyl transpeptidate amin at all transpeptidate amin at all transpeptidate amin and all transpeptidate amin and transpeptidate amin at all transpeptidate amin at a molectil: RAI, rejection a tons, and ETOH. and ETOH. at all transpeptidate amin	34 5.7 100 113 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida atase atase: ALT, alamine amin ataseptida ons. ons and ETOH. ons and ETOH. ons and ETOH.																									
32.7 M HCV 143 542 388 229 5 0 0	over 3 statistical constraint statistican statistica	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 nat glutamyl transpeptidate amin at mofetil: RAI, rejection at oms. ons. and ETOH.	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase; ALT, alamine amin ataseptida anime ma glutamyl transpeptida ons. ons. ons and ETOH. ons and ETOH.	•	49.4	M	HCV and ETOH		5.7			551	172	ß	2	0	30%	moderate		4	0	10	750 mg		Delayed			
	3 32.7 M HCV 143 1.2 447 542 398 229 5 0 0 $$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	 143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 150.5 248.8 308.1 14aase: AUT, alamine amin and glutamyl transpetidiation a glutamyl transpetidi	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase; ALT, alamine amin ataseptida ataseptida atase and glutamyl transpeptida anis anis ons and ETOH. ons and ETOH. ons and ETOH.																				over 3	sepsis, bile	response,			
32.7 M HCV 143 1.2 447 542 398 229 5 0 0 ⁻¹ ⁻¹ 0 0 000mg to text and text	3 32.7 M HCV 143 1.2 447 542 398 229 5 0 0 - - - - - - - - - - - -	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidate amin ma glutamyl transpeptidate amin ma glutamyl transpeptidate amin and some at a drift FOH.	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase; ALT, alamine amin mataseptida at aglutamyl transpeptida temofettl; RAI, rejection and endents ons and ETOH.																				days	duct	7 weeks			
32.7 M HCV 143 1.2 447 542 398 229 5 0 ⁴ ⁴ ³ 0 0 100 mg Cholangtis 60.8 F Cyptogenic 12 61.2 20 67 199 460 6 0 0 10 100 mg 0	3 32.7 M HCV 143 1.2 447 542 398 229 5 0 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidate amin ma glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpeptidate amin at a glutamyl transpectidate amin at a glutamyl transpectidate amin at a glutamyl transpectidate amin at a glutamyl transpectidate amin at a glutamyl transpectidate amin at a glutamy	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin attaseptitida ma glutamyl transpeptida temofettl; RAI, rejection and and and and and and and and and an																					stricture,				
32.7 M HCV 143 1.2 447 542 398 229 5 0 ⁴ ⁵ 0 ⁵ 0 000 mg 0 000 mg 0 000 mg 0 0.054 md 1 60.8 F Cyptogenic 12 62 20 67 199 460 6 0 0 0 100 mg Not on MMF 1 0 100 mg Not on MMF 1 0 10 100 mg Not on MMF 1 0 10 100 mg Not on MMF 1 0 10 100 mg Not on MMF N 0 0 10 100 mg Not on MMF N 0 0 10 100 mg Not on MMF N 0 0 10 100 mg Not on MMF N <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td> <td>143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 213.3 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidate amin ma glutamyl transpeptidate amin and glutamyl transpeptidate amin at a glutamyl transpeptidate amin and glutamyl transpeptidate amin ans at a glutamyl transpeptidate amin ans ans at a glutamyl transpeptidate ans ans at a glutamyl transpeptidate ans ans</td> <td>143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida at aglutamyl transpeptida temofettl; RAI, rejection and ons ons and ETOH.</td> <td></td> <td>severe</td> <td></td>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 217 1.3 195 213.3 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 at a glutamyl transpeptidate amin ma glutamyl transpeptidate amin and glutamyl transpeptidate amin at a glutamyl transpeptidate amin and glutamyl transpeptidate amin ans at a glutamyl transpeptidate amin ans ans at a glutamyl transpeptidate ans ans at a glutamyl transpeptidate ans ans	143 1.2 447 542 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida at aglutamyl transpeptida temofettl; RAI, rejection and ons ons and ETOH.																					severe				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0 0.01 0.01 0.00 <t< td=""><td>$\begin{array}{cccccccccccccccccccccccccccccccccccc$</td><td>1.4.0 1.2 6.2 20 67 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 atase: ALT, alamine amin an glutamyl transpeptida an a glutamyl transpeptida te mofetil: RAI, rejection a ons. ons. ons.</td><td>1.2 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida te mofetti. RAI, rejection and and and and and and and and and an</td><td>~</td><td>100</td><td>М</td><td>TUT I</td><td></td><td>с -</td><td></td><td></td><td>000</td><td>000</td><td>u</td><td>c</td><td>c</td><td></td><td>**</td><td></td><td>ua:</td><td>C</td><td>c</td><td>1000</td><td>Cholangitis</td><td>Dolorod</td></t<>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1.4.0 1.2 6.2 20 67 12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 atase: ALT, alamine amin an glutamyl transpeptida an a glutamyl transpeptida te mofetil: RAI, rejection a ons. ons. ons.	1.2 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida te mofetti. RAI, rejection and and and and and and and and and an	~	100	М	TUT I		с -			000	000	u	c	c		**		ua:	C	c	1000	Cholangitis	Dolorod			
	$ \begin{bmatrix} 60.8 & F & Cryptogenic & 12 & 6.2 & 20 & 67 & 199 & 460 & 6 & 0 & 0 & 0 & mod & - & 4.3 & 0 & 10 & 1000 & mg & not on MMF Responded \\ \hline 0000000000000000000000000000000000$	$ \begin{bmatrix} 60.8 & F & Cryptogenic & 12 & 6.2 & 20 & 67 & 199 & 460 & 6 & 0 & 0 & mod & - & 4.3 & 0 & 10 & 1000 \text{ mg} \text{ Not on MMF Responded} \\ \hline UT & 53.2 & F & Cryptogenic & 217 & 1.3 & 195 & 412 & 197 & 26 & 4 & 0 & 0 & - & - & - & 6.4 & 0 & 15 & 1500 \text{ mg} \text{ Not on MMF Responded} \\ \hline an & 52.4 & 74.0 & 7.3 & 150.5 268.8 308.1 285.5 & 5.1 & 0.3 & 0.0 & 0 & - & - & - & - & 6.4 & 0 & 15 & 1500 \text{ mg} \text{ Not on MMF Responded} \\ \hline ucced circles F, F & Cryptogenic & 217 & 1.3 & 195 & 412 & 197 & 26 & 4 & 0 & 0 & - & - & - & - & 6.4 & 0 & 15 & 1500 \text{ mg} \text{ Not on MMF Responded} \\ \hline an & 52.4 & 74.0 & 7.3 & 150.5 268.8 308.1 285.5 & 5.1 & 0.3 & 0.0 & 1.1 & 744 & 6.9 \\ \hline ucced circles F, Renale GF, Renale GF, Renale GF, Renale antiotransferase: AST, aspartate antiotransferase; CSA cyclosportine A: DDLT, deceased donor liver transplant; FTOH, alcohol-suptimation antiotance index; SD, standard deviation; Tacro, tarcolimus. Compliant for medications. Let the control activity index; SD, standard deviation; Tacro, tarcolimus. Loss for medications. Let the control activity index; SD, standard deviation; Tacro, tarcolimus. Let the control liver transplant; ETOH, alcohol-superation activity index; SD, standard deviation; Tacro, tarcolimus. Let the control liver transplant; LTA, liver activity index; SD, standard deviation; Tacro, tarcolimus. Let the control liver transplant; LTA, liver transplant; LTA, liver activity index; SD, standard deviation; Tacro, tarcolimus. Let the control liver transplant; LTA, the control liver transplant; LTA, liver transp$	12 6.2 20 67 217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ma glutamyl transpeptida te mofettl: RAI, rejection ε ons. and FTOH. entine	12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida atase atase: ALT, alamine amin ataseptida ons ons and ETOH. ons and ETOH. ons	~	1.70	M	лс		1.2			080	677	n	0	D		Ì	I	Ì	D	D	1000 IIIg	OII USA, IIOU	Delayeu			
	$ \begin{array}{ c c c c c c c c c c$	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin aglutamyl transpetida te mofetil: RAI, rejection ε ons. ons. ons. ons.	12 6.2 20 67 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 atase: ALT, alamine amin ataseptida atase ma glutamyl transpeptida temofetti: RAI, rejection at ons. ons and ETOH. ons and ETOH.																				davs		10 weeks			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	LT 53.2 F Cryptogenic 217 1.3 195 412 197 26 4 0 0 - - 6.4 0 15 1500 mg Not on MMF Responded ans 53.2 F Cryptogenic 217 1.3 195 412 197 26 4 0 0 - - 6.4 0 15 1500 mg Not on MMF Responded ans 52.4 74.0 7.3 150.5 2688 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 days an 52.4 76.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 oreeriations: Alk PO4, alkaline phosphatase: AL7, alamine aminotransferase: AS7, aspartate aminotransferase; CsA, cyclosportine A: DDL7, deceased donor liver transplant; E70H, alcohol-noted cirrhosis; LDL7, deceased donor liver transplant; E70H, alcohol-noted cirrhosis; LDL7, ive donor liver transplant; L7X, liver used distribution from the distrine distribution from the distribution from the distribution from t	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	217 1.3 195 412 217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptidate te mofetil: RAI, rejection ε ons. ons and ETOH.	217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptida te mofetti. RAI, rejection a ons.	_	60 S	Ĺ	Cryntogenic		6.2			1 00	460	g	0	C	C	pom	I	4.3	C	10	1000 mg		Resnonded			
53.2 F Cyptogenic 217 1.3 195 412 197 26 4 0 0 - 6.4 0 15 1500 mg 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 0wer 3	LT 53.2 F Cryptogenic 217 1.3 195 412 197 26 4 0 0 - - 6.4 0 15 1500 mg Not on MMF Responded am 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 strend cirrhosis Alk alkaline phosphatase: AL7, alamine aminotransferase; AST, aspartate aminotransferase; CSA, cyclosporine A; DDLT, deceased donor liver transplant; ETOH, alcohol-uccle cirrhosis; LDLT, ilve donor liver transplant; ETOH, alcohol-uccle cirrhosis; LDLT, ilve donor liver transplant; ETOH, alcohol-uccle cirrhosis; LDLT, ilve donor liver transplant; LTX, liver	LT 53.2 F Cryptogenic 217 1.3 195 412 197 26 4 0 0 $ 6.4$ 0 15 150 mg Not on MMF Responded an 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 days 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 $-$ 6.4 $-$ 0 15 150 mg Not on MMF Responded reactions: Alk PO4, alkaline phosphatase: ALT, alanine aminotransferase: AST, aspartate aminotransferase: CSA, cyclosporine A; DDLT, deceased donor liver transplant; ETOH, alcohol- uced cirrbosis: F, female: GGTP, gamma glutamyl transpeptidase; HAI, hepatitis activity index; HCV, hepatitis C viral infection-related cirrbosis; LDLT, live donor liver transplant; LTX, liver se 80 was noncompliant for medications.	217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 πatase; ALT, alamine amin ma glutamyl transpeptida te mofetil: RAI, rejection ε ons. ons.	217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptida te mofetti. RAI, rejection a ons.	_	0.00	-	CI J Progerine		7.0			COT	8	0	>	þ	0	non		D.H	þ	01	over 3		mmindent			
53.2 F Ctyptogenic 217 1.3 195 412 197 26 4 0 0 $ 15$ 1500 mg 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.1 7.1 74.4 6.9	LT 53.2 F Cryptogenic 217 1.3 195 412 197 26 4 0 - - 6.4 0 15 1500 mg Not on MMF Responded 53.2 F Cryptogenic 217 1.3 195 412 197 26 4 0 - - 6.4 0 15 1500 mg Not on MMF Responded an 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 1.1 744 6.9 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 over 34 over 34 0 1.1 744 6.9 over 34 0 1.1 744 6.9 over 34 1.1 744 6.9 over 34 0 1.1 744 6.9 over 34 0 1.1 744 6.9 0 0 1.1	LT 53.2 F Cryptogenic 217 1.3 195 412 197 26 4 0 0 $ -$ 6.4 0 15 150 mg Not on MMF Responded an 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 revirations: AR PO4, alkaline phosphatase: ALT, alarine aminotransferase: AST, aspartate aminotransferase: CSA, cyclosporine A; DDLT, deceased donor liver transplant; ETOH, alcohol- uced circhosis; F, female: GGTP, gamma glutamyl transpetidase: HAI, hepatitis activity index; HOV, hepatitis C viral infection-related circhosis; LDLT, live donor liver transplant; LTM, liver use an ocompliant for medications.	217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptida te mofetil: RAI, rejection a ons. ons.	217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 iatase: ALT, alamine amin ma glutamyl transpeptida te mofetti: RAI, rejection a ons.																				days					
53.2 F Cyptogenic 217 1.3 195 412 197 26 4 0 0 - - 6.4 0 15 1500 mg over 3 51.1 51.1 51.1 6.50 8.8 0 15.1 625.0 8.8 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 20.7 1.4 0.7 0.0 1.1 744 6.9	53.2 F Cyptogenic 217 1.3 195 412 197 26 4 0 - - - 6.4 0 15 1500 mg Not on MMF Responded an 52.4 74.0 7.3 150.5 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 breviations: Alk PO4, alkaline phosphatase: AL7, alarine aminotransferase: AS7, aspartate aminotransferase: CsA, cyclosporine A; DDL7, deceased donor liver transplant; E7OH, alcohol-uccle transcists; F, female: GGTP, gamma glutany) transperiations: All hepatits activity index; HOV, hepatitis Cyrini infection-related cirrhosis; LDL7, live donor liver transplant; L7X, liver uccle transplant; L7X, uccle transplant	53.2 F Cyptogenic 217 1.3 195 412 197 26 4 0 0 - - 6.4 0 15 1500 mg Not on MMF Responded am 52.4 740 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 newiations: Alk 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 newiations: Alk PO4, alkaline phosphatase: ALT, alamine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant: ETOH, alcohol-uced cirrhosis: F, female: GGTP, gamma glutamyl transpeptidase: HAI, hepatitis activity index: HCV, hepatitis C viral infection-related cirrhosis: LDLT, live donor liver transplant: LTA, liver donor liver transplant: LTA, liver donor liver transplant: LTA, liver donor donor donor liver transplan	217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptida te mofetil; RAI, rejection a ons.	217 1.3 195 412 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 1.0 148.1 201.7 173.3 1.0 148.1 201.7 173.3 1.0 148.1 201.7 173.3 1.1 7.0 148.1 201.7 173.3 1.1 7.0 148.1 201.7 173.3 1.1 148.1 201.7 173.3 173.3 1.1 201.7 148.1 201.7 173.3 1.1 201.7 148.1 201.7 173.3 1.1 201.7 141.1 repection \$\$\$ 1.1 201.8 1741. repection \$\$\$ 1.1 201.8 201.4 100.8	LT																								
52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9	an 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 days 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 breviations: Alk PO4, alkaline phosphatase: ALT, alamine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A; DDLT, deceased donor liver transplant; ETOH, alcohol- uccle cirrhosis; F, female: GGTP, gamma glutamyl transperiated activity included: Hot, the patitis activity included: Hot, hepatitis activity included: Hot, more than an activity of activity and activity included activity in the control activity intervention and activity included activity in the control activity intervention activity intervention activity intervention activity intervention activity activity intervention activity activ	an 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 days 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 breviations: Alk PO4, alkaline phosphatase: ALT, alamine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant: ETOH, alcohol- uced cirrhosis: F, female: GGTP, gamma glutamyl transpetidase: HAI, hepatitis activity index: HCV, hepatitis C viral infection-related cirrhosis: LDLT, live donor liver transplant: LTX, live negotiant: M, male: MMF, mycophenolate mofetil: RAI, rejection activity index: SD, standard deviation: Tacro, tacrolimus.	 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptida te mofetil; RAI, rejection a ons. 	 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 anine amin tatase; ALT, alamine amin ma glutamyl transpeptida te mofetti: RAI, rejection a ons. 		53.2	٤	Cryptogenic		1.3			197	26	4	0	0				6.4	0	15	1500 mg		Responded			
52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9	an 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 breviations: Alk PO4, alkaline phosphatase: ALT, alamine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A; DDLT, deceased donor liver transplant; ETOH, alcohol- uccle cirrhois: F, female: GGTP, gamma glutamyl transperiations and additional decentry from the control liver transplant; ETOH, alcohol- uccle cirrhois: F, female: GGTP, gamma glutamyl transperiation and additional decentry from the cirrhosis; LDLT, live donor liver transplant; LTX, liver	an 52.4 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 74.0 7.3 150.5 268.8 308.1 285.5 5.1 0.3 0.0 5.1 625.0 8.8 74.0 6.9 7.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 744 6.9 744 6.9 762 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 744 6.9 744 6.9 762 7.0 7	 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 7.0 148.1 anine amin matase; ALT, alamine amin ma glutamyl transpeptida te mofettil; RAI, rejection a ons. 	 7.3 150.5 268.8 308.1 7.0 148.1 201.7 173.3 148.1 201.7 173.3 14ase; ALT, alanine amin tatase; ALT, alanine amin aglutamyl transpeptida the mofetil; RAI, rejection ε the mofetil; RAI, rejection ε tons. 																				over 3					
74.0 7.0 1.3 190.5 26.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744	breviations: Alk PO4, alkaline phosphatase: ALT, alanine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant; ETOH, alcohol- uccle cirrhois: R. PO4, alkaline phosphatase: ALT, alanine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant; ETOH, alcohol- uccle cirrhois: R. More, and and an anotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant; ETOH, alcohol- uccle cirrhois: R. More, and an anotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant; LTX, liver action and an anotran	10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 11.8 744 6.9 12.1 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 13.1 874 6.9 14.1 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 15.1 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 16.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 17.1 744 6.9 18.1 8.1 8.1 8.1 8.1 8.1 8.1 8.1 8.1 8.1	7.0 148.1 201.7 173.3 7.0 148.1 201.7 173.3 iatase; ALT, alamine amin ma glutamyl transpeptida te mofetil: RAI, rejection a ons.	 7.3 LOU.2 200. 0.00.1 7.0 148.1 201.7 173.3 attase: ALT, alamine amin ma glutamyl transpeptida te mofetil; RAI, rejection and ons. 		C L		c T			0000		L L O			c		ŗ		0				days					
10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744	During the second state of the second state of the second	10.7 76.2 7.0 148.1 201.7 173.3 181.0 1.4 0.7 0.0 1.1 744 6.9 breviations: Alk PO4, alkaline phosphatase: ALT, alamine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant; ETOH, alcohol- uced cirrhosis: F, female: GGTP, gamma glutamyl transpeptidase: HAI, hepatitis activity index: HCV, hepatitis C viral infection-related cirrhosis; LDLT, live donor liver transplant; LTX, liver nsplant; M, male: MMF, mycophenolate mofetil; RAI, rejection activity index: SD, standard deviation; Tacro, tacrolimus.	7.0 148.1 201.7 173.3 atase; ALT, alamine amin ma glutamyl transpeptida te mofetti! RAI, rejection (ons.	7.0 148.1 201.7 173.3 tatase: ALT, alamine amin ma glutamyl transpeptida te mofetil; RAI, rejection 2 ons. ons and ETOH.	an	52.4		74.0		6.06I	268.8		C.CS2.			0.0		1.c	0.029	x x									
	breviations: Alk PO4, alkaline phosphatase: ALT, alamine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A; DDLT, deceased donor liver transplant; ETOH, alcohol- uced cirrhosis: F, female: GGTP, gamma glutamyl transpeptidase: HAI, hepatitis activity index; HCV, hepatitis C viral infection-related cirrhosis; LDLT, live donor liver transplant; LTX, liver activity index; M, and M, and M, and M, and M, and M, and And And And And And And And M,	breviations: Alk PO4, alkaline phosphatase: ALT, alarnine aminotransferase: AST, aspartate aminotransferase: CsA, cyclosporine A: DDLT, deceased donor liver transplant; ETOH, alcohol- luced cirrhosis; F, female: GGTP, gamma glutamyl transpeptidase; HAI, hepatitis activity index; HCV, hepatitis C viral infection-related cirrhosis; LDLT, live donor liver transplant; LTX, liver nsplant; M, male: MMF, mycophenolate mofetil; RAI, rejection activity index; SD, standard deviation; Tacro, tacrolimus.	iatase; ALT, alamine amin ma glutamyl transpeptida te mofetil; RAI, rejection a ons. ons and ETOH.	tatase: ALT, alamine amin ma glutamyl transpeptida te mofetil; RAI, rejection a ons. ons and ETOH.	_	10.7		76.2		148.1	201.7		181.0			0.0		1.1	744	6.9									

IA	$\mathbf{D}\mathbf{D}\mathbf{D}\mathbf{D}$ 0. Ka	ate of Acute Rejection in So	Sinc i ablistica Staales	
			Rate of Acute	
	No. of	Immunosuppression	Rejection at 12	Rate of Steroid
Author	Cases	Protocol	Months	Resistant Rejection (%
Jain et al. ²⁸	28	IV MMF + low-dose	10.7%*	Not give
		tacrolimus + steroids		_
Gonzalez et al. ⁷	180	Dual therapy: tacrolimus	40.7% (dual therapy);	4.4% (dual therapy
		+ steroids; triple	24.4% (triple	2.3% (triple therapy
		therapy: tacrolimus +	therapy) [†]	
		steroids + azathioprine		
Fagiuali et al. ³³	3323	Variable	43.50%	19.10
Boillot et al. ³⁴	245	Dual therapy: tacrolimus	38.0% (dual therapy);	7% (dual therapy); 7.40
		+ steroids; triple	37.9% (triple therapy)	(triple therap
		therapy: tacrolimus +		
		steroids + azathioprine		
Jain et al. ²⁴	350	Dual therapy: tacrolimus	45.2% (dual therapy);	4% (dual therapy); 2.8°
		+ steroids; triple	38.9% (triple therapy)	(triple therap
		therapy: tacrolimus +		
		steroids + oral MMF		
Eckhoff et al. ¹⁶	130	Study: tacrolimus + oral	26% (study); 45%	0% (study); 6.259
		MMF + steroids;	(control)	(contro
		controls: tacrolimus +		
		steroids		
Wiesner et al. ⁸	529	Cyclosporine +	76% (cyclosporine);	36% (cyclosporine); 190
		azathioprine + steroids;	68% (tacrolimus)	(tacrolimus
		tacrolimus + steroids		
Fung et al. ⁹	154	Tacrolimus + steroids;	63.8% (tacrolimus);	Not give
		cyclosporine + steroids	83.2% (cyclosporine)	
US Multicenter FK506 Liver	529	Tacrolimus + steroids;	58.55% (tacrolimus);	16.34% (tacrolimus
Study Group ³¹		cyclosporine +	65.03% (cyclosporine)	30.82% (cyclosporine
		azathioprine + steroids		
European Multicenter FK506	545	Tacrolimus + steroids;	40.5% (tacrolimus);	0.8% (tacrolimus); 5.3%
Liver Study Group ³²		cyclosporine + steroids	49.8% (cyclosporine)	(cyclosporine

Abbreviations: IV, intravenous; MMF, mycophenolate mofetil.

*Mean follow-up of 17 months.

[†]Rate of rejection at 3 months.

and compliment levels may be useful for providing an effective rejection-free immunosuppression regime that is well tolerated in clinical practice without causing overimmunosuppression.

This is a single-center nonrandomized study; however, we do not believe that this precludes our observation of a low rate of rejection with IV MMF, tacrolimus, and steroids in post-LTx patients. Prospective randomized multicenter trials would, however, be useful to confirm our findings.

In conclusion, our observation suggests that IV use of MMF immediately after LTx, in combination with oral tacrolimus and steroids, may provide rejection-free status in a majority of LTx recipients. This may be related to the peak concentration and bioavailability of IV MMF being more than twice that of oral MMF in the immediate post-LTx period.

REFERENCES

 Canafax DM, Ascher NL. Cyclosporine immunosuppression. Clin Pharm 1983;2:515-524. CO. Immunosuppression and other nonsurgical factors in the improved results of liver transplantation. Semin Liver Dis 1985;5:334-343.

- 3. Williams JW, Peters TG, Vera SR, Britt LG, van Voorst SJ, Haggitt RC. Liver transplantation with cyclosporine and low-dose corticosteroids. Am Surg 1985;51:155-157.
- Colonna JO II, Goldstein LI, Brems JJ, Vargas JH, Brill JE, Berquist WJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroidresistant liver transplant rejection. Arch Surg 1987;122: 1120-1123.
- 5. Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999;230:441-448.
- 6. Jain AB, Kashyap R, Rakela J, Starzl TE, Fung JJ. Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg 1999;5:144-150.
- Gonzalez MG, Madrazo CP, Rodriguez AB, Gutiérrez MG, Herrero JI, Pallardó JM, et al. An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: a comparison of dual vs. triple drug therapy. Liver Transpl 2005;11:515-524.
- 8. Wiesner RH. A long-term comparison of tacrolimus
- 2. Starzl TE, Iwatsuki S, Shaw BW Jr, Gordon RD, Esquivel

(FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998;66:493-499.

- Fung JJ, Eliasziw M, Todo S, Jain A, Demetris AJ, Mc-Michael JP, et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996;183:117-125.
- Bechstein WO, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. Transplant Proc 1996;28:1008-1010.
- 11. Fung JJ, Todo S, Tzakis A, Demetris A, Jain A, Abu-Elmaged K, et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc 1991;23(pt 1):14-21.
- 12. Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW Jr, et al., for the US Multicenter FK 506 Liver Study Group. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. Transplant Proc 1993;25(pt 1):635-637.
- Bismuth H, Samuel D, Neuhaus P, McMaster P, Calne R, Pichlmayr R, et al. Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A. Transpl Int 1994;7(suppl 1): S3–S6.
- 14. Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. Clin Transplant 1995;9:406-414.
- 15. Klupp J, Bechstein WO, Platz KP, Keck H, Lemmens HP, Knoop M, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation—first results. Transpl Int 1997;10:223-228.
- Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998;65:18-187.
- 17. Gruttadauria S, Vasta F, Mandala L, Cintorino D, Piazza T, Spada M, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 2005;37:2611-2613.
- 18. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001;7:473-484.
- McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001;7:701-708.
- 20. Fung J, Marcos A. Rapamycin: friend, foe, or misunderstood? Liver Transpl 2003;9:469-472.
- 21. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
- 22. Yashima Y, Ohgane T. Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent [in Japanese]. Nippon Yakurigaku Zasshi 2001;117: 131-137.
- 23. Manzia TM, De Liguori Carino N, Orlando G, Toti L, De Luca L, D'Andria D, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc 2005;37:2616-2617.
- 24. Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophe-

nolate mofetil in primary adult liver transplantation: a single center report. Transplantation 2001;72:1091-1097.

- 25. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11:750-759.
- 26. Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001;41:268-276.
- 27. Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005;45:34-41.
- 28. Jain A, Mohanka R, Orloff M, Abt P, Kashyap R, Kelley M, et al. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation. Exp Clin Transplant 2005;3:361-365.
- Jain A, Venkataramanan R, Kwong T, Mohanka R, Orloff M, Abt P, et al. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl 2007;13:791-796.
- Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
- 31. US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331: 1110-1115.
- 32. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-428.
- Fagiuali S, Mirante VG, Pompili M, Gianni S, Leandro G, Rapaccini GL, et al. Liver transplantation: the Italian experience. Dig Liver Dis 2002;34:640-648.
- 34. Boillot O, Baulieux J, Wolf P, Messner M, Cherqui D, Gugenheim J, et al. Low rejection rates with tacrolimusbased dual and triple regimens following liver transplantation. Clin Transplant 2001;15:159-166.
- 35. Wiesner RH, Steffen BJ, David KM, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. Am J Transplant 2006;6:1609-1616.
- 36. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-324.
- 37. Ensom MH, Partovi N, Decarie D, Ignaszewski AP, Fradet GJ, Levy RD. Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother 2003;37:1761-1767.
- 38. Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer R, Schröder H, et al. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit 2005;27:315-321.
- 39. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000;22:14-19.